How would you like to have an orchidectomy for advanced prostatic cancer?
One hundred thirteen patients were randomized for the study. There was no significant difference between the groups for response or survival. The incidence of side effects related to the reduction of testosterone was similar in both groups. Disease "flare" was seen in three patients treated with long-acting D-Trp-6 LH-RH. All symptoms resolved by the end of 8 weeks. There was less psychological morbidity in the D-Trp-6 LH-RH group but the difference did not reach statistical significance. Our results indicate that long-acting D-Trp-6 LH-RH offers a safe and effective alternative to surgical orchidectomy.
Parmar
H
H
Charing Cross and Westminster Medical School, London, England.
Phillips
R H
RH
Lightman
S L
SL
Edwards
L
L
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003258:Consumer Behavior; D005640:Follicle Stimulating Hormone / Q000032:analysis; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000032:analysis; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000601:surgery; D009919:Orchiectomy / Q000009:adverse effects; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000601:surgery*; D011897:Random Allocation; D012074:Remission Induction; D013739:Testosterone / Q000032:analysis; D017329:Triptorelin Pamoate
D000970:Antineoplastic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone